サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1778334

C型肝炎治療薬の世界市場：疾患タイプ別、薬剤クラス別、流通チャネル別、地域別、機会、予測、2018年～2032年

Global Hepatitis C Drugs Market Assessment, By Disease Type, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 242 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
C型肝炎治療薬の世界市場：疾患タイプ別、薬剤クラス別、流通チャネル別、地域別、機会、予測、2018年～2032年
出版日: 2025年07月29日
発行: Markets & Data
ページ情報: 英文 242 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のC型肝炎治療薬の市場規模は、予測期間の2025年～2032年のCAGRが3.72％となり、2024年の195億1,000万米ドルから2032年には261億4,000万米ドルに成長すると予測されています。C型肝炎治療薬市場は、感染率の増加、疾患に対する認識、高い治癒率と副作用の少ない直接作用型抗ウイルス薬の使用増加により、着実に拡大しています。また、政府プログラム、より優れた診断法、早期スクリーニングプログラムにより、世界のあらゆる地域で治療の普及が進んでいます。

開発途上地域におけるヘルスケアへのアクセスの向上、手頃な価格のジェネリック医薬品、公衆衛生機関による治療選択肢の継続的な支援などが、開発の原動力となっています。医薬品パートナーは、政府、公衆衛生機関、世界の啓発プログラムとともに、C型肝炎撲滅に向けた努力と目標を加速させていくと思われます。さらに、患者一人ひとりのニーズに合わせた治療選択肢を提供する製薬会社の能力が高まっている個別化医療の到来は、技術革新と治療の可能性を促進し続けています。

例えば、2024年3月、Teva UK LimitedとClosed Loop Medicine Ltdは、Tevaの医薬品とClosed Loopのデジタル投薬プラットフォームを組み合わせて個別化医薬品を開発する戦略的提携を発表しました。

当レポートでは、世界のC型肝炎治療薬市場について調査し、市場の概要とともに、疾患タイプ別、薬剤クラス別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界のC型肝炎治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • 疾患タイプ別
      • 急性C型肝炎
      • 慢性C型肝炎
    • 薬剤クラス別
      • HCVプロテアーゼ阻害剤
      • HCVポリメラーゼ阻害剤
      • HCV NSSA阻害剤
      • 併用療法
      • インターフェロンと抗ウイルス
      • ペグインターフェロンアルファ2a
      • ペグインターフェロンアルファ2b
      • リバビリン
      • その他
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第6章 北米のC型肝炎治療薬市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のC型肝炎治療薬市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋のC型肝炎治療薬市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米のC型肝炎治療薬市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカのC型肝炎治療薬市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場の促進要因
  • 市場の課題

第17章 市場動向と発展

第18章 規制枠組みとイノベーション

  • 規制当局の承認
  • 臨床試験

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Lupin Limited
    • AbbVie Inc.
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Janssen Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Zydus Pharmaceuticals, Inc.

第22章 戦略的提言

第23章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 3. Global Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 4. Global Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global Hepatitis C Drugs Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 8. North America Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 9. North America Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America Hepatitis C Drugs Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 13. United States Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 14. United States Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 17. Canada Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 18. Canada Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 21. Mexico Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 22. Mexico Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 25. Europe Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 26. Europe Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe Hepatitis C Drugs Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 30. Germany Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 31. Germany Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 34. France Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 35. France Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 38. Italy Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 39. Italy Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 42. United Kingdom Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 43. United Kingdom Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 46. Russia Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 47. Russia Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 50. Netherlands Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 51. Netherlands Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 54. Spain Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 55. Spain Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 58. Turkey Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 59. Turkey Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 62. Poland Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 63. Poland Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. South America Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 66. South America Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 67. South America Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. South America Hepatitis C Drugs Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 71. Brazil Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 72. Brazil Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. Argentina Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 75. Argentina Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 76. Argentina Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Asia-Pacific Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 79. Asia-Pacific Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 80. Asia-Pacific Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Asia-Pacific Hepatitis C Drugs Market Share (%), By Country, 2018-2032F
  • Figure 82. India Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 84. India Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 85. India Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 86. China Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 88. China Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 89. China Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Japan Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 92. Japan Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 93. Japan Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. Australia Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 96. Australia Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 97. Australia Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 98. Vietnam Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 100. Vietnam Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 101. Vietnam Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 102. South Korea Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 104. South Korea Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 105. South Korea Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. Indonesia Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 108. Indonesia Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 109. Indonesia Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Philippines Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 112. Philippines Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 113. Philippines Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 116. Middle East & Africa Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 117. Middle East & Africa Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa Hepatitis C Drugs Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 121. Saudi Arabia Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 122. Saudi Arabia Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 125. UAE Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 126. UAE Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa Hepatitis C Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Hepatitis C Drugs Market Share (%), By Disease Type, 2018-2032F
  • Figure 129. South Africa Hepatitis C Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 130. South Africa Hepatitis C Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13765

Global hepatitis C drugs market is projected to witness a CAGR of 3.72% during the forecast period 2025-2032, growing from USD 19.51 billion in 2024 to USD 26.14 billion in 2032. The hepatitis C drugs market is increasing steadily due to increasing infection rates, awareness of the disease, and increased use of direct-acting antiviral drugs that are associated with high cure rates and fewer side effects. Government programs, better diagnostics, and early screening programs have also improved the uptake of treatment in all parts of the world.

Growth drivers include increased access to healthcare in developing areas, affordable generic drugs and public health agencies continuing to support treatment options. Pharmaceutical partners, together with governments, public health agencies, and global awareness programs, will continue to accelerate efforts and goals aimed at eliminating Hepatitis C. Moreover, the arrival of personalised medicine, a growing capability of drug companies to provide treatment options tailored to individual patient needs, continues to drive innovation and treatment availability.

For instance, in March 2024, Teva UK Limited and Closed Loop Medicine Ltd announced a strategic partnership to develop personalised medicines by combining Teva's drugs with Closed Loop's digital dosing platform.

Rising Hepatitis C Cases Drive Market Growth

The rise in hepatitis C cases is the leading driver for the growth of the hepatitis C drug market. Hepatitis C will continue to be a problem due to unsafe clinical practices, contaminated blood transfusions and health care scarcity. In regions of the globe with limited access to healthcare, there is a limited ability to screen for hepatitis C. This leads to an increasing number of untreated, undiagnosed hepatitis C cases. Once people discover they have hepatitis C, they get tested and diagnosed. The development of all direct-acting antiviral drugs, which can cure hepatitis C in high percentages and with shorter durations, has disrupted the treatment paradigm for hepatitis C. In addition, pharmaceutical companies have opened access to therapies, including a variety of generic drugs and international collaborations, creating significantly more accessible treatment options. As the incidence of hepatitis C continues to rise, more cases are being diagnosed. In other healthcare and treatment settings, the hepatitis C drug market is expected to continue growing.

For instance, according to the data published in the Viral Hepatitis Surveillance Report - United States, 2023 by the Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Prevention, Centers for Disease Control and Prevention, a total of 4,966 acute hepatitis C cases were reported by 47 states and the District of Columbia, corresponding to an estimated 69,000 acute infections. Additionally, 101,525 newly reported chronic hepatitis C cases were recorded by 45 states and the District of Columbia in 2023. There were 11,194 hepatitis C-related deaths reported.

Technological Innovations Drive Growth of the Global Hepatitis C Market

The hepatitis C drug market landscape is changing rapidly, primarily due to the introduction of advances in new technologies, which are making treatment easier, more effective, more accessible, and more tailored to patients' needs. At the heart of these advances are direct-acting antiviral therapies-simple, all-oral treatments, which can cure a person of the hepatitis C virus, with only mild side effects. In addition, genomic screening is an exciting new technology that allows doctors to determine which therapy a person is likely to respond to best by examining their genotype, as well as their treatment history for both the person and the virus. Public health programs are becoming increasingly important in taking an active approach to public health, through community testing, early diagnosis, and education about the virus. This approach is helping to eradicate the virus. Each of these advances takes us nearer to the goal of eliminating hepatitis C as a public health threat.

For instance, in March 2025, the UK Health Security Agency launched a whole genome sequencing service to strengthen efforts in tackling hepatitis C, marking another step toward England's continued progress in eliminating the virus as a public health threat.

For instance, in June 2025, AbbVie Inc. received expanded FDA approval for Mavyret (glecaprevir and pibrentasvir), making it the first approved treatment for acute hepatitis C virus infection. The approval allows earlier intervention in both adults and children aged three and older, with or without compensation for cirrhosis, improving access to timely care.

Combination Therapy Dominates Hepatitis C Drug Market Size

Combination therapy has quickly become the established segment in the hepatitis C drug market due to its ability to target the virus directly in multiple ways. By using different classes of antiviral agents, combination therapies target the virus in several physiological ways during several phases of the viral life cycle. Combination therapies have also been shown to have the capability of spellbinding single-drug treatments by providing more successful building blocks of therapy, reducing the risk of antiviral resistance, and subsequently reducing the treatment time from 12 months or longer to as short as 8 weeks. Additionally, clinicians typically demonstrate that combination regimens are very well tolerated and feasible for large categories of patients (including those with other co-morbid medical conditions). Combination therapy, through these means, has truly simplified treatment regimens, thereby minimizing the degree of patient disability from the disease and improving their life outcomes as appropriate. The simplification of treatment and improvement of patient outcomes have led to combination therapy being the predominant choice among other physicians and a primary driver of growth in the hepatitis C drug market.

In May 2025, Atea Pharmaceuticals, Inc. announced the results of a Phase 2 trial for an 8-week oral regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV), showing a 98% sustained virological response (SVR12) rate in treatment-adherent patients. The regimen was well tolerated, with a low risk of drug-drug interactions and no dose adjustments required for hepatic or renal impairment.

North America Dominates the Hepatitis C Drugs Market Size

North America is the world leader for hepatitis C drugs due to many factors, including high spending on healthcare, developed medical system capabilities, and a substantial population susceptible to the disease. The U.S. is facing a significant burden of hepatitis C due to large amounts of intravenous drug use, an aging population, and increasing rates of chronic liver disease. The region has early access to new direct-acting antiviral (DAA) drugs that have improved treatment outcomes with higher cure rates and fewer side effects compared to previous treatments. Furthermore, with a more developed regulatory environment in the U.S. and Canada, there is a more proactive reimbursement mechanism that supports most patients receiving therapeutic alternatives. The collaboration among pharmaceutical companies, research institutions, and governments has significantly advanced the treatment of hepatitis C and the development of hepatitis C drugs. These factors are compounded by the high investments made by North America into healthcare and public health initiatives that will help solidify the region as a leader in the hepatitis C drug market.

For instance, in November 2024, bioLytical Laboratories Inc. announced the availability of its INSTI HCV Antibody Test in Canada, following authorization by Health Canada. This rapid test enhances access to hepatitis C diagnosis, supporting ongoing efforts to improve treatment and disease management in the region.

Impact of U.S. Tariffs on the Global Hepatitis C Drugs Market

The U.S. tariffs on hepatitis C drugs could create widespread effects on both domestic and international markets. If tariffs are raised on imported pharmaceutical drugs or raw materials, the prices for treatment will likely increase, and may be unaffordable for patients, especially in low- and middle-income countries. Pharmaceutical companies may have increased operational costs which can lead to increased pricing or shortages of important pharmaceuticals due to disruptions in the global supply chain. This increased cost may divert resources away from research and development (R&D) on current R&D pipelines, further delaying important innovations for hepatitis C treatment. Generic drugs predominately made in countries such as India, may be exploited and exploited prices could in turn limit reducing price competition on access to treatment as generic drug production will be exceptionally exploited. Greater trade hostility may also fracture collaborative global health initiatives related to hepatitis C, negatively affecting international efforts to eradicate hepatitis C. Overall, U.S. tariffs on hepatitis C drugs could create barriers to progressing a more equitable access to life saving medicines especially from within resource poor settings.

Key Players Landscape and Outlook

The hepatitis C drug market is rapidly growing and transforming. Ongoing research in antiviral therapies and the introduction of personalized treatment strategies have permitted the market to expand rapidly. The market is transitioning towards safer, more targeted segments. Highly effective direct-acting antivirals (DAAs) are undergoing a fundamental shift in the treatment landscape, with a variety of new drugs designed to overcome issues with drug resistance and relapse rates. New combination therapies, including innovative classes of antivirals (such as protease inhibitors and polymerase inhibitors), will further raise cure rates and reduce treatment durations.

The increasing competitiveness amongst pharmaceutical companies has been driven by the need to fulfill the unmet clinical needs of patients suffering from chronic hepatitis C, specifically for treatment-naive patients, patients with advanced liver disease, and patients who have resistant strains of hepatitis C. Furthermore, regulatory agencies around the world are approving innovative therapies at a staggering pace, allowing many new drugs to enter the market at a rapid rate. Similarly, AbbVie, Inc.'s all-oral regimen, Mavyret, provides a simpler and more convenient option for patients, while also simplifying adherence. Merck & Co., Inc. also focuses on access to therapies and continually expanding access to treatments with Zepatier, particularly for underrepresented populations worldwide.

Big pharmaceutical companies are constantly innovating, working to develop shorter and more effective therapies while expanding access to established treatments. There is a significant investment of research and development funds aimed at developing the next best thing to conquer hepatitis C, while also providing a fair-priced product for both wealthy and resource-limited markets. These companies are committed to innovation while pursuing diverse access strategies. The outlook for the hepatitis C drug market is bright as the Key Player landscape continues to innovate.

For instance, in April 2025, AbbVie Inc., a global biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its updated hepatitis C treatment, Mavyret (glecaprevir/pibrentasvir), offering a shorter and more effective treatment regimen for hard-to-treat hepatitis C genotypes.

For instance, in April 2025, Gilead Sciences, Inc. announced that it would present its latest advancements in the treatment of Primary Biliary Cholangitis and Viral Hepatitis at an upcoming medical conference. These presentations will highlight new research and data on innovative therapies, showcasing the company's ongoing commitment to improving treatment outcomes for patients with liver diseases.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Hepatitis C Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Disease Type
      • 5.2.1.1. Acute Hepatitis C
      • 5.2.1.2. Chronic Hepatitis C
    • 5.2.2. By Drug Class
      • 5.2.2.1. HCV Protease Inhibitors
      • 5.2.2.2. HCV Polymerase Inhibitors
      • 5.2.2.3. HCV NSSA Inhibitors
      • 5.2.2.4. Combination Therapy
        • 5.2.2.4.1. Ledipasvir and Sofosbuvir
        • 5.2.2.4.2. Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir
        • 5.2.2.4.3. Elbasvir and Grazoprevir
        • 5.2.2.4.4. Others
      • 5.2.2.5. Interferon and Antiviral
      • 5.2.2.6. Peginterferon Alfa 2a
      • 5.2.2.7. Peginterferon Alfa 2b
      • 5.2.2.8. Ribavirin
      • 5.2.2.9. Others
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Disease Type
    • 5.3.2. By Drug Class
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Hepatitis C Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Disease Type
      • 6.2.1.1. Acute Hepatitis C
      • 6.2.1.2. Chronic Hepatitis C
    • 6.2.2. By Drug Class
      • 6.2.2.1. HCV Protease Inhibitors
      • 6.2.2.2. HCV Polymerase Inhibitors
      • 6.2.2.3. HCV NSSA Inhibitors
      • 6.2.2.4. Combination Therapy
        • 6.2.2.4.1. Ledipasvir and Sofosbuvir
        • 6.2.2.4.2. Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir
        • 6.2.2.4.3. Elbasvir and Grazoprevir
        • 6.2.2.4.4. Others
      • 6.2.2.5. Interferon and Antiviral
      • 6.2.2.6. Peginterferon Alfa 2a
      • 6.2.2.7. Peginterferon Alfa 2b
      • 6.2.2.8. Ribavirin
      • 6.2.2.9. Others
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Hospital Pharmacies
      • 6.2.3.2. Retail Pharmacies
      • 6.2.3.3. Online Pharmacies
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Hepatitis C Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Disease Type
          • 6.3.1.2.1.1. Acute Hepatitis C
          • 6.3.1.2.1.2. Chronic Hepatitis C
        • 6.3.1.2.2. By Drug Class
          • 6.3.1.2.2.1. HCV Protease Inhibitors
          • 6.3.1.2.2.2. HCV Polymerase Inhibitors
          • 6.3.1.2.2.3. HCV NSSA Inhibitors
          • 6.3.1.2.2.4. Combination Therapy
          • 6.3.1.2.2.4.1. Ledipasvir and Sofosbuvir
          • 6.3.1.2.2.4.2. Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir
          • 6.3.1.2.2.4.3. Elbasvir and Grazoprevir
          • 6.3.1.2.2.4.4. Others
          • 6.3.1.2.2.5. Interferon and Antiviral
          • 6.3.1.2.2.6. Peginterferon Alfa 2a
          • 6.3.1.2.2.7. Peginterferon Alfa 2b
          • 6.3.1.2.2.8. Ribavirin
          • 6.3.1.2.2.9. Others
        • 6.3.1.2.3. By Distribution Channel
          • 6.3.1.2.3.1. Hospital Pharmacies
          • 6.3.1.2.3.2. Retail Pharmacies
          • 6.3.1.2.3.3. Online Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Hepatitis C Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Hepatitis C Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Hepatitis C Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Hepatitis C Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Regulatory Approvals
  • 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Teva Pharmaceutical Industries Ltd.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. F. Hoffmann-La Roche Ltd
    • 21.3.3. GlaxoSmithKline plc
    • 21.3.4. Lupin Limited
    • 21.3.5. AbbVie Inc.
    • 21.3.6. Gilead Sciences, Inc.
    • 21.3.7. Bristol-Myers Squibb Company
    • 21.3.8. Janssen Pharmaceuticals, Inc.
    • 21.3.9. Merck & Co., Inc.
    • 21.3.10. Zydus Pharmaceuticals, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer